StreetInsider.com News Articles

PreveCeutical closes first tranche of private placement at $0.03 per unit

Thu, 22 Oct 2026 17:26:14 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) has closed the initial tranche of a non-brokered private placement, raising $156,000 through the issuance of 5,200,000 units priced at $0.03 each, according to a company statement.

The total offering is targeted at $600,000, with the company planning to close a second tranche in the coming weeks. Each unit consists of one common share and one-half of a share purchase warrant. Each whole warrant allows the holder to purchase an additional share at $0.06 for two years from closing, subject to an acceleration clause if the share price reaches $0.11 or more

PreveCeutical closes first tranche of private placement at $0.03 per unit

Thu, 22 Oct 2026 17:26:14 -0400

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Thu, 22 Oct 2026 17:24:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce that, further to its news release dated September 28, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $600,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 5,200,000 units (each, a "Unit") of the Company at a price of $0.03 per Unit for gross aggregate proceeds of $156,000. PreveCeutical intends to close a second tranche for the remainder of the Offering in the coming weeks.

Each Unit is

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Thu, 22 Oct 2026 17:24:00 -0400

Each Unit is

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Thu, 22 Oct 2026 17:24:00 -0400

Each Unit is

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Thu, 22 Oct 2026 17:24:00 -0400

Each Unit is

PreveCeutical plans private placement to raise up to $600,000

Mon, 28 Sep 2026 17:01:13 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced a non-brokered private placement of up to 20,000,000 units at $0.03 per unit, seeking gross proceeds of up to $600,000.

Each unit consists of one common share and one-half of one share purchase warrant. Each whole warrant allows the holder to purchase one additional share at $0.06 per share for two years from closing. The warrants may expire early if the closing price of the company's common shares on the Canadian Securities Exchange reaches $0.11 or higher for at least 10 consecutive trading days and a notice of acceleration is issued.

According

PreveCeutical plans private placement to raise up to $600,000

Mon, 28 Sep 2026 17:01:13 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced a non-brokered private placement of up to 20,000,000 units at $0.03 per unit, seeking gross proceeds of up to $600,000.

According

PreveCeutical Announces Non-Brokered Private Placement

Mon, 28 Sep 2026 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 20,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.03 per Unit for gross proceeds of up to $600,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share")

PreveCeutical Announces Non-Brokered Private Placement

Mon, 28 Sep 2026 17:00:00 -0400

PreveCeutical Announces Non-Brokered Private Placement

Mon, 28 Sep 2026 17:00:00 -0400

PreveCeutical Announces Non-Brokered Private Placement

Mon, 28 Sep 2026 17:00:00 -0400

PreveCeutical closes fourth tranche, raising $1M in total placement

Tue, 04 Aug 2026 17:22:10 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) has closed the fourth tranche of a non-brokered private placement, issuing 8,600,000 units at $0.025 per unit for gross proceeds of $215,000, according to a press release.

Combined with three earlier tranches closed in May, June, and July 2026, the company has raised aggregate gross proceeds of $1,000,000 from the offering. The first tranche raised $340,000, the second raised $245,000, and the third raised $200,000.

Each unit consists of one common share and one-half of a share purchase warrant. Each whole warrant allows the holder to purchase one additional share at $0.05 for

PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement

Tue, 04 Aug 2026 17:20:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated July 27, 2026, June 12, 2026, May 12, 2026 and April 22, 2026 (the "Prior News Releases"), it has closed a fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Offering"), which Fourth Tranche consisted of the issuance of 8,600,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $215,000. The Company closed an

PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement

Tue, 04 Aug 2026 17:20:00 -0400

PreveCeutical closes third tranche, raising $200,000 in placement

Mon, 27 Jul 2026 17:14:10 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) has closed the third tranche of its non-brokered private placement, issuing 8,000,000 units at $0.025 per unit for gross proceeds of $200,000, according to a company statement.

The third tranche brings the aggregate proceeds from all three tranches to $785,000. The initial tranche, closed May 12, 2026, raised $340,000 through 13,600,000 units, while the second tranche, closed June 12, 2026, raised $245,000 through 9,800,000 units.

Each unit consists of one common share and one-half of a share purchase warrant. Each whole warrant allows the holder to purchase one additional share at $0.05 for

PreveCeutical Closes Third Tranche of Non-Brokered Private Placement

Mon, 27 Jul 2026 17:12:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated June 12, 2026, May 12, 2026 and April 22, 2026, it has closed a third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Offering"), which Third Tranche consisted of the issuance of 8,000,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $200,000. The Company closed an initial tranche (the "Initial Tranche") on May

PreveCeutical Closes Third Tranche of Non-Brokered Private Placement

Mon, 27 Jul 2026 17:12:00 -0400

PreveCeutical closes second tranche of private placement for $245,000

Fri, 12 Jun 2026 17:41:14 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced the completion of a second tranche of its non-brokered private placement, raising $245,000 through the issuance of 9.8 million units priced at $0.025 each.

The company previously closed an initial tranche on May 12, 2026, which raised $340,000 through 13.6 million units. Combined proceeds from both tranches totaled $585,000.

Each unit consists of one common share and one-half of a share purchase warrant. The warrants allow holders to purchase additional shares at $0.05 per share for two years from the closing date. The company retains an acceleration right that can shorten the

PreveCeutical Closes Second Tranche of Non-Brokered Private Placement

Fri, 12 Jun 2026 17:39:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 9,800,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $245,000. The Company closed an initial tranche (the "Initial Tranche") on May 12, 2026, consisting

PreveCeutical Closes Second Tranche of Non-Brokered Private Placement

Fri, 12 Jun 2026 17:39:00 -0400

BioGene Therapeutics appoints Ty Howton to board of directors

Mon, 08 Jun 2026 03:02:18 -0400

BioGene Therapeutics Inc. appointed Ty Howton to its board of directors, effective immediately, according to a statement from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0).

Howton brings nearly 30 years of biopharmaceutical industry experience, including 15 years in executive roles at public and private companies. He currently serves as Chief Operating Officer of Solid Biosciences, a clinical-stage gene therapy company, where he oversees daily operations and has helped advance multiple candidates into clinical trials.

His previous executive positions include Chief Operating Officer and General Counsel of AavantiBio, which merged with Solid Biosciences in 2022, and Executive Vice President, General Counsel

BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors

Mon, 08 Jun 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effective immediately. Mr. Howton has extensive board and governance experience, having previously served as Board Counsel and Corporate Secretary for Solid Biosciences, AavantiBio, Sarepta Therapeutics, and Vertex Pharmaceuticals, as well as Advisor to the Board on Health

BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors

Mon, 08 Jun 2026 03:00:00 -0400

PreveCeutical extends private placement deadline to June 12

Tue, 19 May 2026 19:37:14 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced it has extended the closing date of its non-brokered private placement to June 12, 2026, and plans to close a second tranche by the same date.

The offering aims to raise $1,000,000 through the sale of units. Each unit consists of one common share and one-half share purchase warrant. The warrants allow holders to purchase additional shares at $0.05 each for two years from closing, subject to acceleration provisions if shares trade at $0.10 or higher for ten consecutive trading days on the Canadian Securities Exchange.

The company stated it intends to